Debby P. M. van den Bogaert, MD, Ellen M

Slides:



Advertisements
Similar presentations
Su K. Metcalfe, MD, MPH, Michael T
Advertisements

Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 
Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung  Sai-Hong.
Outcome for Patients with Malignant Pleural Mesothelioma Referred for Trimodality Therapy in Western Australia  Arman Hasani, MBBS, FRACP, John M. Alvarez,
Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis  Ian Cromwell, MSc, Kimberly.
Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor,
Epidemiology of Environmental Exposure and Malignant Mesothelioma
Phase II Clinical Trial of First or Second-Line Treatment with Bortezomib in Patients with Malignant Pleural Mesothelioma  Dean A. Fennell, PhD, FRCP,
Epidemiology of Environmental Exposure and Malignant Mesothelioma
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Phase II Trial with Carboplatin and Bendamustine in Patients with Extensive Stage Small-Cell Lung Cancer  Wolf Köster, MD, Andrea Heider, MD, Norbert.
The Role of Radiation Therapy in Malignant Thymoma: A Surveillance, Epidemiology, and End Results Database Analysis  Annemarie T. Fernandes, BA, Eric.
Pleurectomy/Decortication, Hyperthermic Pleural Lavage with Povidone-Iodine Followed by Adjuvant Chemotherapy in Patients with Malignant Pleural Mesothelioma 
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Phase I Trial of Cediranib in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Unresectable Malignant Pleural Mesothelioma (SWOG.
Incidence and Survival of Malignant Pleural Mesothelioma in Norway: A Population- Based Study of 1686 Cases  Åslaug Helland, MD, PhD, Steinar Solberg,
A Randomized Phase II Study Adding Axitinib to Pemetrexed-Cisplatin in Patients with Malignant Pleural Mesothelioma: A Single-Center Trial Combining Clinical.
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
The Use of Systemic Treatment in the Maintenance of Patients with Non–Small Cell Lung Cancer: A Systematic Review  Swati Kulkarni, MD, Emily T. Vella,
Patterns of Care and Treatment Outcomes of Elderly Patients with Stage I Esophageal Cancer: Analysis of the National Cancer Data Base  Amy C. Moreno,
Electronic Updates for JTO Readers
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
Karin J. C. Sanders, MD, Lizza E. Hendriks, MD, Esther G. C
Surgical Treatment for Octogenarians with Lung Cancer: Results from a Population- Based Series of 124 Patients  Hes A.P. Brokx, MD, Otto Visser, MD, PhD,
John E. Pilling, FRCS (CTh), Michael E
An Unusual Presentation of Malignant Pleural Mesothelioma
Prognostic Impact of Malignant Pleural Effusion at Presentation in Patients with Metastatic Non–Small-Cell Lung Cancer  Daniel Morgensztern, MD, Saiama.
Correlation Between Polymorphisms of the Reduced Folate Carrier Gene (SLC19A1) and Survival After Pemetrexed-Based Therapy in Non-small Cell Lung Cancer:
A Combined Prognostic Serum Interleukin-8 and Interleukin-6 Classifier for Stage 1 Lung Cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening.
Evaluation of the Recommended Dose and Efficacy of Amrubicin as Second- and Third- Line Chemotherapy for Small Cell Lung Cancer  Satoshi Igawa, MD, PhD,
Single-Agent Versus Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: Prognostic Factors and.
Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline  J Noble,
Jeffrey Bradley, MD, Issam El Naqa, PhD  Journal of Thoracic Oncology 
Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors  Benny Weksler, MD, Anthony Holden, MD, Jennifer.
Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database  Laura C. Caprario, MD, MS,
Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green 
Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD 
Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma  Fauzia Shaikh, MD, Marjorie G. Zauderer,
Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E
PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?  Steven G. Gray, PhD  Journal of Thoracic.
A Randomized Phase II Trial of Two Schedules of Docetaxel in Elderly or Poor Performance Status Patients with Advanced Non-small Cell Lung Cancer  Rogerio.
Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer 
Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III.
Treatment of Malignant Pleural Mesothelioma with Carboplatin, Liposomized Doxorubicin, and Gemcitabine: A Phase II Study  Gunnar Hillerdal, MD, PhD, Jens.
Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded.
Should Patient-Rated Performance Status Affect Treatment Decisions in Advanced Lung Cancer?  Esther Dajczman, RN, MScA, Goulnar Kasymjanova, MD, PhD,
Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011)  Ellen.
It’s All in the “Swerve of the Curve”
Lung Volume Measurements as a Surrogate Marker for Patient Response in Malignant Pleural Mesothelioma  Zacariah E. Labby, PhD, Samuel G. Armato, PhD,
Maintenance Therapy and Advanced Non–Small-Cell Lung Cancer: A Skeptic's View  Martin J. Edelman, MD, Thierry Le Chevalier, MD, Jean-Charles Soria, MD,
Pulmonary Resection for Metastases from Colorectal Cancer
Jie Huang, Juan Peng, Linlang Guo, MD, PhD 
Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J
Roger Hakimian, MD, Hongbin Fang, PhD, Leno Thomas, MD, Martin J
International Thymic Malignancies Interest Group: A Way Forward
A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104  Ramaswamy Govindan, MD, Xiaofei.
Linda L. Garland, MD, Kari Chansky, MS, Antoinette J
A Pathological Complete Response in Malignant Pleural Mesothelioma after Combination Chemotherapy with Carboplatin and Pemetrexed  Steven Chuan-Hao Kao,
Pleural Metastases of Malignant Melanoma
Phase I/II Study of Vinorelbine and Exisulind as First-Line Treatment of Advanced Non- small Cell Lung Cancer in Patients at Least 70 Years Old: A Wisconsin.
A Phase III Randomized Trial of Gemcitabine–Oxaliplatin versus Carboplatin–Paclitaxel as First-Line Therapy in Patients with Advanced Non-small Cell Lung.
David James Pinato, MD, MRes, Francesco A
Treatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer  Giorgio.
Genetic and Proteomic Features Associated with Survival after Treatment with Erlotinib in First-Line Therapy of Non-small Cell Lung Cancer in Eastern.
APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28
Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer  James B. Yu, MD, Roy H. Decker, MD, PhD,
Cytokine Gene Therapy for Malignant Pleural Mesothelioma
A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding.
Nutrition During Trimodality Treatment in Stage III Non-small Cell Lung Cancer: Not Only Important for Underweight Patients  Barbara S. van der Meij,
A Review of First-Line Treatment for Small-cell Lung Cancer
Presentation transcript:

Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma  Debby P.M. van den Bogaert, MD, Ellen M. Pouw, MD, Gerda van Wijhe, Ir, René M. Vernhout, MD, Veerle F.M. Surmont, MD, Henk C. Hoogsteden, MD, Rob J. van Klaveren, MD, PhD  Journal of Thoracic Oncology  Volume 1, Issue 1, Pages 25-30 (January 2006) DOI: 10.1016/S1556-0864(15)31509-4 Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Origin of the 13 patients with malignant pleural mesothelioma who received pemetrexed maintenance therapy. Journal of Thoracic Oncology 2006 1, 25-30DOI: (10.1016/S1556-0864(15)31509-4) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Kaplan-Meier estimates of time to progression for patients with a malignant pleural mesothelioma with and without pemetrexed maintenance therapy after six courses of induction treatment. Journal of Thoracic Oncology 2006 1, 25-30DOI: (10.1016/S1556-0864(15)31509-4) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Kaplan-Meier estimates of overall survival time for patients with a malignant pleural mesothelioma with and without pemetrexed maintenance therapy after six courses of induction treatment. Journal of Thoracic Oncology 2006 1, 25-30DOI: (10.1016/S1556-0864(15)31509-4) Copyright © 2006 International Association for the Study of Lung Cancer Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.